From the blog

MesoTRAP: A Study Comparing Video-assisted Thoracoscopic Partial Pleurectomy/Decortication With Indwelling Pleural Catheter in Patients With Trapped Lung Due to Malignant Pleural Mesothelioma. (MesoTRAP)

Purpose: Malignant pleural mesothelioma is a cancer, caused by asbestos, which currently affects 2500 people in the UK each year. The main symptom is breathlessness caused by fluid building up in the space between the lung and the chest wall (pleural effusion). Treatment involves draining the fluid to allow the lung to re-expand (pleurodesis). However, sometimes tumour growth over the surface of the lung can prevent it from re-expanding. This ‘trapped’ lung results in fluid re-accumulation and repeated drainage which can lead to discomfort and multiple hospital visits.

One approach to dealing with ‘trapped’ lung in mesothelioma is to insert a thin tube (Indwelling Pleural Catheter – IPC) into the space around the lung. The tube can stay in place for a long time allowing patients to drain off fluid at home.

Another approach is a keyhole surgical operation (video-assisted thoracoscopic partial pleurectomy/decortication – VAT-PD) to remove as much tumour as possible from the lining of the lung to allow it to re-expand.

While both approaches are currently offered in clinical practice, it is not known which of the two is most effective at relieving breathlessness. The only way to find out is to conduct a research trial comparing the two. The Investigators plan to do this, but first of all need to carry out a small pilot study to collect information necessary to help plan the full study.

Read More »

Effective Chemotherapy May Rest Upon Reducing Overactive Enzyme

Chemotherapy for mesothelioma patients has been notoriously difficult and the cancer continues to be overwhelmingly unresponsive to such treatment in many cases. However, researchers and scientists have been continually investigating new techniques that involve adjusting how chemotherapy reacts on a cellular level. A study published in the Frontiers in Pharmacology[…]

Read More »

February is National Cancer Prevention Month

Cancer is the second most leading cause of death in the United States affecting over 500,000 people. However, is estimated that 1/3 of all cancers could be prevented through daily activities such as eating healthy, exercising, or simply applying sunscreen on a sunny day.  Cancers caused by asbestos exposure are[…]

Read More »

The Orphan Drug Act and the National Organization for Rare Disorders Bring Attention and Funding to Rare Diseases

Testing and developing new drugs and treatments for an illness is a costly endeavor, but drug companies thrive in this business by being able to sell medication to the sick – especially those suffering from common conditions. The more common a condition, the more profits drug companies will make selling[…]

Read More »

Gene Therapy and DNA Sequencing for Malignant Mesothelioma

Genes are the basic unit of DNA that creates unique proteins used for specific cellular function. The expression of that gene creates an effect and if a gene cannot make a specific protein, this can lead some health risks or problems. A multifactorial disorder, like cancer, heart disease, and diabetes,[…]

Read More »

Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma

Purpose:The purpose of this study is to find out whether the combination of avelumab and SBRT is safe and what effect avelumab has on mesothelioma when given in combination with SBRT. In addition, a goal of this protocol is to study the effect of radiation therapy on the immune system. It is thought that radiation treatment may create a form of ‘vaccine’ against cancer inside the body and immunotherapy may improve this effect. The combination of radiation treatment and immunotherapy may be more effective against cancer than either radiation or immunotherapy alone.

Read More »

Multimodality Therapy in Pleural Mesothelioma

Even though there is no cure for mesothelioma, there are many different treatment options for those suffering from this almost always fatal cancer. Palliative therapy has been successful in lessening symptoms and making the patient more comfortable. Chemotherapy, radiation therapy, and surgery are treatment methods that can be successful on[…]

Read More »

Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma

Purpose:The purpose of this study is to investigate the clinical efficacy and toxicity of anti-PD-1 monoclonal antibody plus autologous dendritic cells-cytokine induced killer cell (DC-CIK) immunotherapy combined with hyperthermia in advanced malignant mesothelioma patients.Furthermore,to characterize response to therapy, we intent to explore the predictive biomarker for this regimen.

Read More »

An Inaccurate Mesothelioma Prognosis Can Result in Wrong Treatment

Mesothelioma is not easy to diagnose. Symptoms often mimic other ailments and patients often do not make the connection between asbestos exposure and their illness. Once mesothelioma is diagnosed, patients are often given a poor prognosis – typically less than one year. However, with recent advancements in treatments and immunotherapies,[…]

Read More »

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Purpose:This study is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LAG525 as a single agent and in combination with PDR001 to adult patients with solid tumors. The study consists of a dose escalation phase (I) to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) for LAG525 as a single agent and in combination with PDR001, and a dose expansion phase (II) which will characterize treatment of LAG525 as a single agent and in combination with PDR001 at the MTD or RP2D.

Read More »

Skip to content